1. Home
  2. ICCM vs EOCN Comparison

ICCM vs EOCN Comparison

Compare ICCM & EOCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo IceCure Medical Ltd.

ICCM

IceCure Medical Ltd.

HOLD

Current Price

$0.77

Market Cap

3.6M

Sector

N/A

ML Signal

HOLD

EOCN

Eocene Ltd. Ordinary Shares

N/A

Current Price

$2.10

Market Cap

2.9M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
ICCM
EOCN
Founded
2006
2000
Country
Israel
Israel
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.6M
2.9M
IPO Year
2013
2013

Fundamental Metrics

Financial Performance
Metric
ICCM
EOCN
Price
$0.77
$2.10
Analyst Decision
Strong Buy
Analyst Count
3
0
Target Price
★ $22.67
N/A
AVG Volume (30 Days)
★ 118.4K
6.1K
Earning Date
11-23-2026
11-25-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$27.11
N/A
Revenue Next Year
$104.97
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.13
$2.30
52 Week High
$9.54
$3.80

Technical Indicators

Market Signals
Indicator
ICCM
EOCN
Relative Strength Index (RSI) 28.77 32.26
Support Level $0.22 $2.32
Resistance Level $2.50 $3.48
Average True Range (ATR) 0.10 0.30
MACD 0.02 -0.04
Stochastic Oscillator 25.02 23.09

Price Performance

Historical Comparison
ICCM
EOCN

About ICCM IceCure Medical Ltd.

Icecure Medical Ltd is a commercial-stage medical device company. The company is engaged in the research, development, and marketing of cryoablation systems and technologies based on liquid nitrogen, or LN2, for treating tumors. Its cryoablation technology is a minimally invasive alternative to surgical intervention for tumors, including those found in the breast, lungs, kidneys, bones, and other indications.

About EOCN Eocene Ltd. Ordinary Shares

Eocene Ltd is a GI-focused medtech and biopharmaceutical company focused on advancing solutions across gastrointestinal disease management, GI oncology and related therapeutic areas. Its wholly owned subsidiary develops medical devices for postoperative colorectal care, including CG-100, an intraluminal bypass device intended to protect colorectal anastomoses and reduce the need for diverting stomas. The company's therapeutic portfolio includes Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule being evaluated in liver disease and oncology indications, including gastrointestinal cancers.

Share on Social Networks: